Dana Schneider
Ophthalmology · Wesley Chapel, FLNPI 1760914147
Payments from drug & device makers
Across 89 payments — averaging $60.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- Glaukos Corporation$551
- Amgen$377
- AbbVie$356
- Beaver-visitec International, Inc.$350
- Dompe US, Inc.$278
- plus $2K from 15 others
What the payments were for
- Consulting fees$3507%
- Travel & lodging$1,33125%
- Food & beverage$3,65969%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 21 | $1,799 |
| Glaukos Corporation | 5 | $551 |
| Amgen(2 entities) | 9 | $377 |
| AbbVie | 5 | $356 |
| Beaver-visitec International, Inc. | 1 | $350 |
| Dompe US, Inc. | 5 | $278 |
| Apellis Pharmaceuticals, Inc. | 3 | $271 |
| Bausch & Lomb Americas Inc. | 6 | $214 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $174 |
| Sun Pharmaceutical Industries Inc. | 6 | $148 |
| Genentech USA, Inc. | 1 | $147 |
| Tarsus Pharmaceuticals, Inc. | 4 | $137 |
| Alcon | 6 | $121 |
| Regeneron Healthcare Solutions, Inc. | 1 | $114 |
| Oyster Point Pharma, Inc. | 4 | $94 |
| Novartis | 3 | $67 |
| Biotissue Holdings Inc. | 2 | $58 |
| Merz Pharmaceuticals, LLC | 1 | $23 |
| Sight Sciences, Inc. | 1 | $23 |
| Harrow Eye, LLC | 1 | $19 |
| Ocular Therapeutix, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPHTHALMIC INSTRUMENTS$1,258
- TRULIGN TORIC$1,258
- ENVISTA$1,258
- CRYSTALENS$1,258
- DURYSTA$250
- Syfovre$246
- TEPEZZA$243
- VABYSMO$147
- MIEBO$124
- Oxervate$121
- EYLEA HD$114
- iStent Trabecular Micro-Bypass System Model iS3$105
How this compares
$5,340 in reported general payments places this provider in the 70th percentile of 1,405 ophthalmology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 26 | $31,889 |
| XiidraLifitegrast | 14 | $15,119 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $13,519 |
| LumiganBimatoprost | 22 | $13,512 |
| MieboPerfluorohexyloctane/Pf | 14 | $10,772 |
| Lotemax SmLoteprednol Etabonate | 39 | $9,727 |
| RhopressaNetarsudil Mesylate | 12 | $9,560 |
| Latanoprost | 158 | $2,337 |
| Loteprednol Etabonate | 14 | $2,326 |
| Prednisolone Acetate | 42 | $1,806 |
| MoxifloxacinMoxifloxacin Hcl | 52 | $1,581 |
| Timolol Maleate | 52 | $1,350 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 51 | $976 |
| ErythromycinErythromycin Base | 51 | $617 |
| ValacyclovirValacyclovir Hcl | 11 | $597 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $356 | $45,40148 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $214 | $25,89128 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $1,799 | $12,05353 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Wesley Chapel
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.